The DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.
Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Open accessAbstract
Gene delivery/expression vectors have been used as fundamental technologies in gene therapy since the 1980s. These technologies are also being applied in regenerative medicine as tools to reprogram cell genomes to a pluripotent state and to other cell lineages. Rapid progress in these new research areas and expectations for their translation into clinical applications have facilitated the development of more sophisticated gene delivery/expression technologies. Since its isolation in 1953 in Japan, Sendai virus (SeV) has been widely used as a research tool in cell biology and in industry, but the application of SeV as a recombinant viral vector has been investigated only recently. Recombinant SeV vectors have various unique characteristics, such as low pathogenicity, powerful capacity for gene expression and a wide host range. In addition, the cytoplasmic gene expression mediated by this vector is advantageous for applications, in that chromosomal integration of exogenous genes can be undesirable. In this review, we introduce a brief historical background on the development of recombinant SeV vectors and describe their current applications in gene therapy. We also describe the application of SeV vectors in advanced nuclear reprogramming and introduce a defective and persistent SeV vector (SeVdp) optimized for such reprogramming.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Although both methods have low reprogramming efficiency, Sendai virus-mediated reprogramming has been used for several clinical applications, notably, in cystic fibrosis, the AIDS vaccine, and other iPSC replacement therapies [29,30,31,32,33].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [33]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the SeV vector is known as being “ex-gene-free”, several researchers are still unsure of its safety in producing clinical-grade iPSC lines, as the avoidance of transgene integration passively depends on the cell passage [64].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“Reprogramming skin fibroblasts into induced pluripotent stem cells (iPSCs) by the ectopic expression of four reprogramming factors (Oct4, Sox2, Klf4 and c-Myc) opened a new era in this field [48-51].”
BackgroundInduction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 1×
“Reprogramming skin fibroblasts into induced pluripotent stem cells (iPSCs) by the ectopic expression of four reprogramming factors (Oct4, Sox2, Klf4 and c-Myc) opened a new era in this field [48-51].”
BackgroundLipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,978 · cited 1×
“Development of sophisticated gene delivery tools in the 1980s such as retroviral vectors [1, 2], adenoviral vectors [3] and cationic lipidbased reagents [4] facilitated the translation of these technologies to human gene therapy.”
BackgroundGeneration of germline-competent induced pluripotent stem cells
Okita, K., Ichisaka, T., & Yamanaka, S. (2007) · Nature · doi:10.1038/nature05934 · Cited by 4,299
Expression of a single transfected cDNA converts fibroblasts to myoblasts
Davis, R. L., Weintraub, H., & Lassar, A. B. (1987) · Cell · doi:10.1016/0092-8674(87)90585-x · Cited by 3,385 · cited 1×
“The concept of nuclear reprogramming was first proposed in the 1970s, based on experiments with somatic cell fusion and was proven by the discovery of MyoD, a gene encoding a master transcription factor inducing the dynamic transition of fibroblasts to myoblasts [47].”
BackgroundStem Cells, the Molecular Circuitry of Pluripotency and Nuclear Reprogramming
Jaenisch, R., & Young, R. (2008) · Cell · doi:10.1016/j.cell.2008.01.015 · Cited by 1,427
FUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411 · cited 1×
“Wild-type SeV vectors installed with Oct4, Sox2, Klf4 and cMyc cDNA were reported to generate ex-gene-free iPSCs, dependent on passive elimination of the genome through cell passage [54].”
BackgroundIn vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes
Qian, L., Huang, Y., Spencer, C. I., Foley, A., Vedantham, V., Liu, L., Conway, S. J., Fu, J.-D., & Srivastava, D. (2012) · Nature · doi:10.1038/nature11044 · Cited by 1,360
Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000305204.97355.0d · Cited by 1,174
Research works printed but not linked: 1
- [11]Lamb RA Kolakofsky D Paramyxoviridae: The Viruses and Their Replication Fundamental Virology Fourth Edition 2001 689 724
Cited by
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
“It is favored for its high but transient gene expression levels, wide host cell specificity, low pathogenicity, and strong immunogenicity [120].”
BackgroundDevelopments in Viral Vector-Based Vaccines
Ura, T., Okuda, K., & Shimada, M. (2014) · Vaccines · doi:10.3390/vaccines2030624 · Cited by 436
“The SeV vector has been used for gene therapy and in a vaccine in human trials [13,97].”
MethodViral vector‐based gene therapies in the clinic
Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10258 · Cited by 269
Kwon, H., Kim, M., Seo, Y., Moon, Y. S., Lee, H. J., Lee, K., & Lee, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.034 · Cited by 208
Omole, A. E., & Fakoya, A. O. J. (2018) · PeerJ · doi:10.7717/peerj.4370 · Cited by 204
Metadata
- Authors
- Nakanishi, M., & Otsu, M.
- Affiliations
- National Institute of Advanced Industrial Science and Technology (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Corresponding author
- Nakanishi, Mahito
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-09-01
- Volume
- 12
- Issue
- 5
- Pages
- 410-416
- ISSN
- 1566-5232 (ISSN-L)
- PMC
- PMC3504922
- OpenAlex
- W2008332694
- Cited by
- 147
- References
- 70
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 19 · 2023: 7 · 2022: 12 · 2021: 11 · 2020: 13 · 2019: 14 · 2018: 15 · 2017: 13 · 2016: 6 · 2015: 8 · 2014: 6 · 2013: 6
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Current Gene Therapy (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (24659489)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Sendai virus, recombinant viral vectors, gene therapy, regenerative medicine, nuclear reprogramming, pluripotency, gene delivery
- MeSH terms
- Animals, Genetic Vectors, Humans, Genetic Therapy, Gene Expression, Gene Transfer Techniques, Sendai virus, Regenerative Medicine, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine. https://app.cochat.ai/papers/10.2174/156652312802762518
- The paper
- Nakanishi, M., & Otsu, M. (2012). Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine. Current Gene Therapy. https://doi.org/10.2174/156652312802762518
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.